esomeprazole + amoxicillin + clarithromycin + metronidazole

This is a four-drug combination therapy consisting of esomeprazole, amoxicillin, clarithromycin, and metronidazole. It is used primarily for the eradication of Helicobacter pylori infection in the gastrointestinal tract. Esomeprazole is a proton pump inhibitor that suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme in gastric parietal cells, creating an environment that enhances antibiotic efficacy. Amoxicillin is a broad-spectrum beta-lactam antibiotic that inhibits bacterial cell wall synthesis. Clarithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. Metronidazole acts as a nitroimidazole antimicrobial agent effective against anaerobic bacteria and protozoa; it disrupts DNA structure and inhibits nucleic synthesis in susceptible organisms. This quadruple regimen targets H. pylori through multiple mechanisms to overcome increasing rates of resistance seen with dual or triple therapies involving these agents individually or in smaller combinations[2][3][5][6]. The combination exploits different mechanisms of action to maximize eradication rates and minimize resistance development.

Other names

Qo-14Qo14Qo 14